AXSM stock forecast, quote, news & analysis
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company... Show more
Axsome Therapeutics (AXSM) Stock Analysis: Auvelity's Alzheimer's Milestone
Key Takeaways
- Axsome Therapeutics received FDA (Food and Drug Administration) approval for Auvelity in treating agitation associated with Alzheimer's disease dementia, driving shares to record highs.
- Analysts raised price targets, with consensus around $224, reflecting optimism on pipeline expansion.
- Q1 2026 earnings due May 4, expected to show continued revenue growth from Auvelity and Sunosi.
- Stock has exhibited strong upward momentum in recent weeks amid regulatory catalysts.
- Market cap exceeds $10 billion, underscoring commercial-stage biopharma positioning in CNS (central nervous system) disorders.
Current Market Snapshot
In recent trading sessions, Axsome Therapeutics (AXSM) stock has demonstrated robust upward momentum, propelled by key regulatory advancements and positive analyst sentiment. Shares have climbed significantly within the latest market cycle, reflecting investor enthusiasm for the company's expanding CNS portfolio. Trading volume has surged alongside price gains, indicating heightened interest from institutional players. The stock's position near its 52-week high signals strength, supported by solid commercial performance from approved therapies like Auvelity and Sunosi. Broader biotech sector tailwinds have complemented company-specific drivers, positioning AXSM favorably amid evolving market dynamics.
Trending AI Robots
Tickeron's Trending AI Robots page curates the top-performing AI trading bots from its library of over 350 bots that trade thousands of tickers across diverse strategies, timeframes, and market conditions. These bots employ advanced AI and machine learning for real-time signals, with virtual agents offering automated risk management and signal agents requiring no minimum balance. Current trending bots focus on high-momentum sectors like semiconductors, data centers, and AI infrastructure, showcasing annualized returns ranging from 23% to over 164%, win rates of 51% to 88%, and strategies such as AI Trading Agents with corridor take-profit/stop-loss levels or fundamental analysis. For instance, semiconductor-focused bots have delivered up to 98% annualized returns on tickers like NVDA and AMD, while volatility plays exceed 160% returns. These curated selections highlight bots best suited to prevailing volatility and trends. Traders can explore these to potentially enhance strategies—visit the page to copy top performers today.
Recent Developments Driving AXSM Price Action
Axsome Therapeutics (AXSM) stock has experienced notable price appreciation in recent weeks, largely tied to pivotal regulatory and corporate milestones. On April 8, the company announced its Q1 2026 financial results release scheduled for May 4, ahead of the market open, accompanied by a conference call. This update builds on strong Q4 2025 performance, where net product revenue hit $196 million—a 65% year-over-year increase—surpassing estimates, with EPS of -$0.56 beating consensus by $0.14.
Analyst activity intensified, bolstering sentiment. UBS raised its price target from $251 to $259 on April 10, maintaining a Buy rating, while Morgan Stanley adjusted from $207 to $217 on April 30. Consensus now stands at approximately $224 across 22 analysts, predominantly Buy ratings. These revisions reflect confidence in Axsome's commercial traction and pipeline.
The catalyst propelling the sharpest move was the FDA's approval on April 30 of Auvelity (dextromethorphan-bupropion) for agitation associated with dementia due to Alzheimer’s disease, marking a label expansion into a market potentially worth billions. Trading was briefly halted that day pending news, after which shares surged over 12% to a record high above $217, with elevated volume exceeding 2.8 million shares—far above average. The approval, following priority review granted in late 2025, positions Auvelity for a June launch, with Axsome hosting an investor event featuring experts on May 1 to discuss implications.
Prior anticipation had already lifted shares, with commentary noting an "attractive setup" ahead of the PDUFA (Prescription Drug User Fee Act) date and the stock nearing buy points around $191 in mid-April. Macro factors, including biotech sector gains, provided tailwinds, but company-specific news dominated, shifting sentiment from pipeline risk to revenue diversification. Investors now eye Q1 results for updates on sales force expansion to 600 representatives and gross-to-net dynamics. Overall, these events have linked directly to AXSM's price strength, underscoring the market's reward for execution in CNS therapeutics.
2026 Outlook and Key Factors to Monitor
As Axsome Therapeutics advances through 2026, investors should track several strategic elements shaping its trajectory in the CNS space. The recent Auvelity approval opens avenues for revenue growth via label expansion, complementing established sales from major depressive disorder and narcolepsy indications. Upcoming Q1 results on May 4 will offer insights into commercialization momentum, including sales force scaling and payer dynamics.
Pipeline progress remains central: AXS-12 for narcolepsy and AXS-14 for fibromyalgia target potential 2026 approvals, while solriamfetol explores major depressive disorder with excessive daytime sleepiness. Phase 3 trial initiations, such as CLARITY for solriamfetol, could advance these assets. Regulatory milestones, patent settlements like the recent Teva resolution, and gross-to-net trends will influence margins amid SG&A (selling, general, and administrative) investments.
Broader factors include Alzheimer's market expansion, competitive positioning against undifferentiated therapies, and biotech funding environment. Risks encompass clinical setbacks, reimbursement hurdles, and macroeconomic pressures on healthcare spending. Opportunities lie in Axsome's differentiated oral therapies addressing unmet needs in high-prevalence disorders. Monitoring earnings guidance, PDUFA dates, and analyst updates will be essential for gauging sustained growth potential.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsAXSM's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for AXSM turned positive on June 11, 2026. Looking at past instances where AXSM's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 09, 2026. You may want to consider a long position or call options on AXSM as a result. In of 68 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AXSM advanced for three days, in of 310 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 268 cases where AXSM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for AXSM moved out of overbought territory on June 18, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator moved out of overbought territory. In of the 45 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXSM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AXSM broke above its upper Bollinger Band on June 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AXSM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AXSM's P/B Ratio (238.095) is slightly higher than the industry average of (20.059). P/E Ratio (0.000) is within average values for comparable stocks, (35.871). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.677). AXSM has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (17.794) is also within normal values, averaging (361.315).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of biopharmaceutical services for pain and other nervous system
Industry Biotechnology